b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">\n        <PMID Version="1">31209422</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>08</Month>\n            <Day>07</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>08</Month>\n            <Day>07</Day>\n        </DateRevised>\n        <Article PubModel="Print">\n            <Journal>\n                <ISSN IssnType="Print">1671-167X</ISSN>\n                <JournalIssue CitedMedium="Print">\n                    <Volume>51</Volume>\n                    <Issue>3</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>Jun</Month>\n                        <Day>18</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences</Title>\n                <ISOAbbreviation>Beijing Da Xue Xue Bao</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>[Analysis of prophylactic effect of extended-duration anticoagulant drugs in elderly patients undergoing hip fracture].</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>501-504</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.19723/j.issn.1671-167X.2019.03.018</ELocationID>\n            <Abstract>\n                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the prophylactic effect of extended-duration anticoagulant drugs on venous thromboembolism, and to explore the time of drug prevention for venous thromboembolism after hip fracture.</AbstractText>\n                <AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective analysis of 143 patients undergoing hip fractures from November 2017 to October 2018 in Peking University People\'s Hospital was conducted to investigate the relationship between the extended-duration anticoagulant drug and the morbidity of venous thromboembolism and bleeding during the treatment. All the drug prevention programs for the patients included in the study were implemented in accordance with the 2016 edition of the Guidelines for Prevention of Venous Thrombosis in Orthopaedic Surgery by Orthopaedic Society of Chinese Medical Association. The patients in the two groups were followed up for venous thromboembolism and bleeding during the medication within 5 weeks after the fracture. Venous thromboembolism included symptomatic and asymptomatic deep venous thrombosis of the lower extremities, pulmonary thromboembolism, and all the patients with deep venous thrombosis of the lower extremities required vascular ultrasound results to obtain clear evidence. The results of vascular ultrasound were the basis for determining deep venous thrombosis. Bleeding conditions were included, but not limited to gastrointestinal bleeding, wound bleeding, intracranial hemorrhage, intraspinal hematoma, and fundus hemorrhage.</AbstractText>\n                <AbstractText Label="RESULTS" NlmCategory="RESULTS">There were no pulmonary thromboembolism in both groups after surgery. The morbidity of deep venous thrombosis was 22.09% and 8.77% in the 2-week and 4-week groups (P=0.037), the time to deep venous thrombosis in the two groups was (17.32\xc2\xb17.75) days and (29.20\xc2\xb10.17) days after surgery. One case of bleeding occurred during the use of anticoagulant drugs in both groups, the morbidity of bleeding during the treatment was 1.16% and 1.75% (P=0.769), respectively.</AbstractText>\n                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Extended-duration anticoagulant drugs to 4 weeks after surgery can significantly reduce the morbidity of postoperative venous thromboembolism, and does not increase the risk of bleeding. Patients with a risk of bleeding should carefully assess the risks and benefits of drug prevention and choose the best treatment.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Zhang</LastName>\n                    <ForeName>W</ForeName>\n                    <Initials>W</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Trauma and Orthopaedics, Peking University People\'s Hospital, Beijing 100044, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zhang</LastName>\n                    <ForeName>P X</ForeName>\n                    <Initials>PX</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Trauma and Orthopaedics, Peking University People\'s Hospital, Beijing 100044, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>chi</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>China</Country>\n            <MedlineTA>Beijing Da Xue Xue Bao Yi Xue Ban</MedlineTA>\n            <NlmUniqueID>101125284</NlmUniqueID>\n            <ISSNLinking>1671-167X</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006620" MajorTopicYN="Y">Hip Fractures</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>6</Month>\n                <Day>19</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>6</Month>\n                <Day>19</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>8</Month>\n                <Day>8</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31209422</ArticleId>\n            <ArticleId IdType="doi">10.19723/j.issn.1671-167X.2019.03.018</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'